Table 3.

AML mouse models based on viral transduction and transplantation.

Year	Transgene	Viral Vector	Cellular Target	Phenotype	Ref.
1990	BCR-ABL	pMSCV-pgk-neo	Total BM	Myeloproliferative malignancy, ALL and CML-like	[111]
1997	MLL-ENL	pMSCV-IRES-GFP	Thy-1loSca-1+Hi-2Khi, 5-FU treated BM	Self-renewal in vitro & AML in vivo	[117]
2002	RUNX1-ETO	pMSCV-IRES-GFP	HSC c-Kit + Sca-1 − Lin −	Myeloid developmental abnormality but no AML	[118]
2003	MLL-GAS7	pMSCV-pgk-neo	HSPC	Mixed lineage leukaemia phenotype	[120]
2004	MOZ-TIF2, BCR-ABL	pMSCV-IRES-GFP	CMP, GMP	MOZ-TIF2 but not BCR-ABL resulted in transplantable AML in vivo	[114]
2006	MLL-AF9	pMSCV-IRES-GFP	GMP	Transplantation of transduced cells propagated in MC resulted in AML in vivo	[115]
2011	MN1	pMSCV-pgk-neo	CMP, GMP	CMP are susceptible for MN1 transformation, GMP required co-expression of MEIS1 for AML induction	[121]
2012	MLL-AF9	pMSCV-pgk-puro	Evi1+/− MLL-AF9 transduced cells	Knockdown of Evi1 delayed leukaemia induction in vivo	[116]

FU (Fluorouracil), MC (methylcellulose).